EUVIMEDScopri EUVIMED
Crossref

Clinical outcomes associated with anti‐Xa‐monitored enoxaparin for venous thromboembolism prophylaxis

John A Saunders, Sara R Vazquez iD, Joseph A Hill, Daniel M Witt iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2900 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by John A Saunders and 3 co-authors. Institution: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA. Major MEDLINE topics: Enoxaparin, Venous Thromboembolism. Cited 2 times so far (Crossref); 24 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Study Objective The objective of the study was to assess clinical outcomes (composite of any venous thromboembolism [VTE], any bleeding, and mortality) associated with anti‐Xa monitoring in the 30 days following enoxaparin initiation for VTE prophylaxis.

Design

Retrospective cohort study.

Setting

Hospital within an academic healthcare system. Patients Propensity score‐matched hospitalized adults receiving enoxaparin for VTE prophylaxis.

Intervention

Low‐molecular‐weight heparin anti‐Xa monitoring. Measurements and Main Results During the 13‐month study period, a total of 6611 patients received enoxaparin for VTE prophylaxis, 301 in the anti‐Xa monitored group and 6310 in the unmonitored group (4.6% received monitoring). The mean age was 52.9 years and 52% of patients were male. The mean body mass index was 31 kg/m 2 and the mean creatinine clearance was 109 mL/min. Twenty percent of patients had active cancer. The most common indication for enoxaparin prophylaxis was hospitalization for medical illness (52%) followed by nonorthopedic surgery (37%). The adjusted odds ratio for the primary outcome comparing monitored to unmonitored patients was 1.26 (95% confidence interval, 0.75–2.11). None of the between‐group differences in the individual components of the composite outcome were statistically significant.

Conclusions

Thirty‐day clinical outcomes in patients receiving enoxaparin for VTE prophylaxis were not improved by anti‐Xa monitoring. Our results support current evidence‐based guideline recommendations against anti‐Xa monitoring for patients receiving enoxaparin for VTE prophylaxis.

Subjects

MeSH terms (MEDLINE)

EnoxaparinVenous ThromboembolismAdultHumansMaleMiddle AgedFemaleRetrospective StudiesAnticoagulantsHeparin, Low-Molecular-Weight

Author keywords

anti-factor Xa monitoringdrug monitoringenoxaparinlow-molecular-weight heparinvenous thromboembolism

Substances

EnoxaparinAnticoagulantsHeparin, Low-Molecular-Weight

Authors and institutions

  • Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
  • Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • University of Utah Health Thrombosis Service, Murray, Utah, USA.

ORCID profiles: Sara R Vazquez, Daniel M Witt

Cite

APA

Saunders, J. A., Vazquez, S. R., Hill, J. A., & Witt, D. M. (2024). Clinical outcomes associated with anti‐Xa‐monitored enoxaparin for venous thromboembolism prophylaxis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2900

Vancouver

Saunders JA, Vazquez SR, Hill JA, Witt DM. Clinical outcomes associated with anti‐Xa‐monitored enoxaparin for venous thromboembolism prophylaxis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2900

BibTeX
@article{Saunders2024,
  author = {Saunders, John A and Vazquez, Sara R and Hill, Joseph A and Witt, Daniel M},
  title = {Clinical outcomes associated with anti‐Xa‐monitored enoxaparin for venous thromboembolism prophylaxis},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2900}
}
Start for free →